<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01246193</url>
  </required_header>
  <id_info>
    <org_study_id>130HPS10C</org_study_id>
    <nct_id>NCT01246193</nct_id>
  </id_info>
  <brief_title>CKD-828(80/2.5mg) Pharmacokinetic Study</brief_title>
  <official_title>Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Telmisatan 80mg and S-Amlodipine 2.5mg as a Fixed Dose Combination Tablet Compared With Combination Therapy in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic characteristics of CKD-828(Fixed
      Dose Combination Tablet; Telmisartan and S-Amlodipine) in healthy volunteer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC) and Cmax after administration of CKD-828(Fixed Dose Combination) tablet and co-administration of corresponding dose of Telmisartan and S-Amlodipine as individual tablets.</measure>
    <time_frame>up to 168 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>CKD-828(Fixed Dose Combination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-828(FDC)</intervention_name>
    <description>Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily</description>
    <arm_group_label>CKD-828(Fixed Dose Combination)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination Therapy</intervention_name>
    <description>Drug: Telmisatan 80mg Tablet, Oral, Once Daily
Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily</description>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy volunteer between 20 and 55 years old with body weight within 20% of ideal
             body weight.

          -  Have not any congenital or chronic diseases and medical symptom.

          -  Appropriate for the study judging from examinations(interview, vital signs, 12-lead
             ECG, physical examination, blood, urinalysis result on screening).

          -  Able to participate in the entire trial.

          -  Signed the informed consent form prior to the study participation.

        Exclusion Criteria:

          -  Take metabolic enzyme inducing or inhibiting drugs like barbiturates within 28 days
             prior to the first IP administraion.

          -  The evidence of acute disease within 28 days prior to the first IP administraion.

          -  Disease(ex: imflammatory intestinal disease, gastric or duodenal ulcer ,hepatic
             diseasehistory , gastro intestinal surgery exept for appendectomy)that may influence
             on the absorption, distribution, metabolism and excretion of the drug(s).

          -  Relevant hypersensitivity against drug or clinically significant allergic diseases
             except mild rhinitis that doesn't need medication.

          -  Hypersensitivity Telmisartan or Amlodipine.

          -  SBP&lt;90mmHg or DBP&lt;50mmHg.

          -  Abnormal laboratory result(s): AST or ALT &gt; 1.25 times of upper limit / Total
             bilirubin &gt; 1.5 times of upper limit.

          -  A drug abuse or a heavy caffeine consumer (more than 5 cups per a day) or a heavy
             smoker(more than 10 cigarettes per a day) or a regular alcohol consumer(more than
             30g/day) or drinking within 7days prior to the first IP administration.

          -  Diet(Especially, grapefruit juice-within 7 days prior to the first IP administraion)
             that may influence on the absorption, distribution, metabolism and excretion of the
             drug(s).

          -  Donated whole blood within 60 days prior to the first IP administraion.

          -  Participated in the other clinical trials within 90days prior to the first IP
             administraion.

          -  Medicine within 10 days prior to the first IP administraion? Does the medication
             affect this trial.

          -  A pregnant or nursing women who does not use medically acceptable birth control.

          -  Appropriate for the trial judging from principal investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eunyoung Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje Unuversity Pusan Paik Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje Unuversity Pusan Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <last_update_submitted>January 17, 2011</last_update_submitted>
  <last_update_submitted_qc>January 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jin Kim / Director</name_title>
    <organization>Clincal Research Department</organization>
  </responsible_party>
  <keyword>CKD-828</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Primary Hypertension</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>S-Amlodipine</keyword>
  <keyword>Telmisartan</keyword>
  <keyword>Amlodipine</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

